Related Experiment Video

Updated: May 21, 2026

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Short-term subcutaneous insulin treatment delays but does not prevent diabetes in NOD mice

Vedran Brezar1, Slobodan Culina, Marie-Claude Gagnerault

  • 1INSERM, U986, DeAR Lab Avenir, Cochin/Saint Vincent de Paul Hospital, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

European Journal of Immunology
|June 9, 2012
PubMed

Insights

High-dose insulin in NOD mice delayed type 1 diabetes onset by inducing a temporary beta-cell "rest." Low-dose insulin, similar to human trials, showed no effect, highlighting dose-dependent efficacy in diabetes prevention research.

Area of Science:

  • Immunology
  • Endocrinology
  • Diabetes Research

Background:

  • Type 1 diabetes (T1D) prevention trials using subcutaneous insulin in humans have yielded limited success, contrasting with positive outcomes in NOD mouse models.
  • Discrepancies between mouse models and human trials necessitate investigation into factors influencing insulin's efficacy for T1D prevention.

Purpose of the Study:

  • To investigate the impact of different subcutaneous insulin doses on insulitis and diabetes incidence in NOD mice.
  • To elucidate the immune and metabolic modifications associated with varying insulin dosages in a T1D model.

Main Methods:

  • NOD mice were treated for 7 weeks with either a high dose (0.5 U/mouse) or a low dose (0.005 U/mouse) of subcutaneous insulin.
  • Monitoring included insulitis, diabetes incidence, immune cell composition, Interferon-gamma (IFN-γ) secretion of T cells, blood glucose, and C-peptide levels.

Main Results:

  • Low-dose insulin did not affect disease incidence.
  • High-dose insulin delayed diabetes onset and reduced insulitis, but these effects were transient and reappeared after treatment cessation.
  • No significant changes were observed in islet infiltrate composition or IFN-γ secretion from islet-reactive CD8(+) T cells recognizing specific epitopes (insulin B(15-23), IGRP(206-214)).
  • Delayed diabetes was linked to transiently lower blood glucose and C-peptide levels.

Conclusions:

  • High-dose, but not low-dose, prophylactic insulin treatment can delay diabetes onset in NOD mice.
  • The observed delay is associated with metabolic changes suggesting a temporary beta-cell "rest" that is not sustained post-treatment.
  • Findings underscore the importance of insulin dosage in T1D prevention strategies and suggest potential limitations for human trials using low doses.

More Related Videos

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells06:27

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...